{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:35Z","timestamp":1792714295435,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006098","name":"Radiological Society of North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["5K12CA090625-18"],"award-info":[{"award-number":["5K12CA090625-18"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.radonc.2025.110794","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:05:54Z","timestamp":1739905554000},"page":"110794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["PIM kinase inhibition counters resistance to radiotherapy and chemotherapy in human prostate cancer"],"prefix":"10.1016","volume":"206","author":[{"given":"Anne","family":"Rajkumar-Calkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shania","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarki A.","family":"Abdulkadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-6900","authenticated-orcid":false,"given":"Austin N.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110794_b0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.radonc.2025.110794_b0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrurol.2015.25","article-title":"Radiotherapy for high-risk prostate cancer","volume":"12","author":"Mohiuddin","year":"2015","journal-title":"Nature Reviews. Urology"},{"key":"10.1016\/j.radonc.2025.110794_b0015","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/american college of radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.radonc.2025.110794_b0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"International JournalRadiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110794_b0025","first-page":"897","article-title":"Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"Journal of the American Medical Association (JAMA)Oncol"},{"key":"10.1016\/j.radonc.2025.110794_b0030","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-5347(05)65855-7","article-title":"High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer","volume":"166","author":"Zelefsky","year":"2001","journal-title":"The Journal of Urology"},{"key":"10.1016\/j.radonc.2025.110794_b0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2009.07.1680","article-title":"Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics","volume":"78","author":"Heemsbergen","year":"2010","journal-title":"International JournalRadiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110794_b0040","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ijrobp.2005.10.002","article-title":"Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer","volume":"64","author":"Peeters","year":"2006","journal-title":"International JournalRadiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110794_b0045","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"European Urology"},{"key":"10.1016\/j.radonc.2025.110794_b0050","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"CancerDiscov"},{"key":"10.1016\/j.radonc.2025.110794_b0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s40425-019-0704-z","article-title":"Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer","volume":"7","author":"Dudzinski","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.radonc.2025.110794_b0060","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"CancerDiscov"},{"key":"10.1016\/j.radonc.2025.110794_b0065","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.biocel.2004.11.005","article-title":"The serine\/threonine kinase Pim-1","volume":"37","author":"Bachmann","year":"2005","journal-title":"International JournalBiochem Cell Biol"},{"key":"10.1016\/j.radonc.2025.110794_b0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jcp.2005.027672","article-title":"Overexpression of Pim-1 during progression of prostatic adenocarcinoma","volume":"59","author":"Cibull","year":"2006","journal-title":"Journal of Clinical Pathology"},{"key":"10.1016\/j.radonc.2025.110794_b0075","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/onc.2010.10","article-title":"Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma","volume":"29","author":"Wang","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2025.110794_b0080","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/onc.2011.371","article-title":"Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells","volume":"31","author":"Wang","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2025.110794_b0085","series-title":"PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance","author":"Holder","year":"2013"},{"key":"10.1016\/j.radonc.2025.110794_b0090","series-title":"PIM Kinase (and Akt) Biology and Signaling in Tumors","author":"Warfel","year":"2015"},{"key":"10.1016\/j.radonc.2025.110794_b0095","doi-asserted-by":"crossref","first-page":"23837","DOI":"10.18632\/oncotarget.8070","article-title":"PIM1 destabilization activates a p53-dependent response to ribosomal stress in cancer cells","volume":"7","author":"Sagar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2025.110794_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-021-01915-1","article-title":"Direct phosphorylation and stabilization of HIF-1\u03b1 by PIM1 kinase drives angiogenesis in solid tumors","author":"Casillas","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2025.110794_b0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-0109-y","article-title":"PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer","volume":"5","author":"Luszczak","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.radonc.2025.110794_b0110","doi-asserted-by":"crossref","first-page":"21770","DOI":"10.1074\/jbc.M113.458851","article-title":"The PIM-2 kinase is an essential component of the ultraviolet damage response that acts upstream to E2F-1 and ATM","volume":"288","author":"Zirkin","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.radonc.2025.110794_b0115","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bbrc.2016.03.099","article-title":"Pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells","volume":"473","author":"Chen","year":"2016","journal-title":"The Biochemist Biophys Res Commun"},{"key":"10.1016\/j.radonc.2025.110794_b0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2012.01.004","article-title":"Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair","volume":"319","author":"Hsu","year":"2012","journal-title":"Cancer Letters"},{"key":"10.1016\/j.radonc.2025.110794_b0125","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju407","article-title":"PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer","volume":"107","author":"Kirschner","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.radonc.2025.110794_b0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1748-717X-2-4","article-title":"Counting colonies of clonogenic assays by using densitometric software","volume":"2","author":"Niyazi","year":"2007","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2025.110794_b0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2025.110794_b0140","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-020-18013-7","article-title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer","volume":"11","author":"Vatapalli","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.radonc.2025.110794_b0145","unstructured":"Andrews S. FastQC: A quality control tool for high throughput sequence data. 2010;http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"10.1016\/j.radonc.2025.110794_b0150","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinforma Oxf Engl"},{"key":"10.1016\/j.radonc.2025.110794_b0155","doi-asserted-by":"crossref","first-page":"D766","DOI":"10.1093\/nar\/gky955","article-title":"GENCODE reference annotation for the human and mouse genomes","volume":"47","author":"Frankish","year":"2019","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.radonc.2025.110794_b0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nature Methods"},{"key":"10.1016\/j.radonc.2025.110794_b0165","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biology"},{"key":"10.1016\/j.radonc.2025.110794_b0170","doi-asserted-by":"crossref","first-page":"W199","DOI":"10.1093\/nar\/gkz401","article-title":"WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs","volume":"47","author":"Liao","year":"2019","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.radonc.2025.110794_b0175","doi-asserted-by":"crossref","first-page":"W130","DOI":"10.1093\/nar\/gkx356","article-title":"WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.radonc.2025.110794_b0180","doi-asserted-by":"crossref","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: the universal protein knowledgebase in 2021","volume":"49","author":"The UniProt Consortium","year":"2021","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.radonc.2025.110794_b0185","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/1471-2164-9-488","article-title":"BioVenn \u2013 a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams","volume":"9","author":"Hulsen","year":"2008","journal-title":"BMC Genomics"},{"key":"10.1016\/j.radonc.2025.110794_b0190","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1755-8794-8-S4-S2","article-title":"LENS: web-based lens for enrichment and network studies of human proteins","volume":"8","author":"Handen","year":"2015","journal-title":"BMC Medical Genomics"},{"key":"10.1016\/j.radonc.2025.110794_b0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","article-title":"Power and sample size calculations. A review and computer program","volume":"11","author":"Dupont","year":"1990","journal-title":"Controlled Clinical Trials"},{"key":"10.1016\/j.radonc.2025.110794_b0200","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0197-2456(98)00037-3","article-title":"Power and sample size calculations for studies involving linear regression","volume":"19","author":"Dupont","year":"1998","journal-title":"Controlled Clinical Trials"},{"key":"10.1016\/j.radonc.2025.110794_b0205","first-page":"25","article-title":"Gene ontology: tool for the unification of biology","volume":"25","author":"Ashburner","year":"2000","journal-title":"The Gene Ontology Consortium Nat Genet"},{"key":"10.1016\/j.radonc.2025.110794_b0210","doi-asserted-by":"crossref","first-page":"D325","DOI":"10.1093\/nar\/gkaa1113","article-title":"The Gene Ontology resource: enriching a GOld mine","volume":"49","author":"Gene Ontology Consortium","year":"2021","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.radonc.2025.110794_b0215","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.119.313763","article-title":"PIM1 (Moloney Murine Leukemia Provirus Integration Site) Inhibition Decreases the Nonhomologous End-Joining DNA Damage Repair Signaling Pathway in Pulmonary Hypertension","volume":"40","author":"Lampron","year":"2020","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.radonc.2025.110794_b0220","doi-asserted-by":"crossref","unstructured":"Lim R, Barker G, Lappas M. Inhibition of PIM1 kinase attenuates inflammation-induced pro-labour mediators in human fetal membranes in vitro. Mol. Hum. Reprod. 2017.","DOI":"10.1093\/molehr\/gax013"},{"key":"10.1016\/j.radonc.2025.110794_b0225","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2008.19.8267","article-title":"MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02","volume":"27","author":"Khor","year":"2009","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.radonc.2025.110794_b0230","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1158\/1078-0432.CCR-14-0075","article-title":"A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02","volume":"20","author":"Pollack","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.radonc.2025.110794_b0235","doi-asserted-by":"crossref","first-page":"18012","DOI":"10.1074\/jbc.M709695200","article-title":"Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma","volume":"283","author":"Hogan","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.radonc.2025.110794_b0240","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neo.2016.01.006","article-title":"MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner","volume":"18","author":"Feng","year":"2016","journal-title":"Neoplasia N Y N"},{"key":"10.1016\/j.radonc.2025.110794_b0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1541-7786.9.2.1","article-title":"Mdm2 in the response to radiation","volume":"2","author":"Perry","year":"2004","journal-title":"Mol Cancer Res MCR"},{"key":"10.1016\/j.radonc.2025.110794_b0250","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/0008-5472.CAN-03-0969","article-title":"p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2\/p14ARF","volume":"64","author":"Xia","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.radonc.2025.110794_b0255","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1038\/onc.2010.279","article-title":"PIM1 kinase is destabilized by ribosomal stress causing inhibition of cell cycle progression","volume":"29","author":"Iadevaia","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2025.110794_b0260","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1124\/dmd.104.002097","article-title":"Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17beta-glucuronide oxidation to 2-hydroxy-estradiol-17beta-glucuronide by CYP 2C8","volume":"33","author":"Delaforge","year":"2005","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.radonc.2025.110794_b0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-nutr-072610-145127","article-title":"Cytochrome P450s in the Regulation of Cellular Retinoic Acid Metabolism","volume":"31","author":"Ross","year":"2011","journal-title":"Annual Review of Nutrition"},{"key":"10.1016\/j.radonc.2025.110794_b0270","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41416-018-0082-1","article-title":"Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers","volume":"118","author":"Cortes","year":"2018","journal-title":"British J Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025000891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025000891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:45:06Z","timestamp":1777553106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025000891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":54,"alternative-id":["S0167814025000891"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110794","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PIM kinase inhibition counters resistance to radiotherapy and chemotherapy in human prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110794"}}